Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $28.0K | $-14.29M | $-0.34 |
| 2024 | $0.00 | $-13.00M | $-0.50 |
| 2023 | $651.0K | $-18.40M | $-1.29 |
| 2022 | $0.00 | $42.52M | $5.73 |
| 2021 | $378.0K | $-35.10M | $-5.86 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.06 per share
Typical surprise +16.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.06 vs $-0.06beat
- Wed, May 13$-0.04 vs $-0.07beat
- Mon, Mar 23$-0.06 vs $-0.07beat
- Wed, Nov 12$-0.11 vs $-0.07miss
- Thu, Aug 14$-0.10 vs $-0.12beat
- Tue, May 13$-0.16 vs $-0.17beat
Estimates and results for TLPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
TLPHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·2d ago·Positive
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·2d ago·Neutral
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments
View source ↗